Latest News

Eureka Forbes (NSE:EUREKAFORB) has had a rough month with its share price down 18%. However, stock prices are usually...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

EBITDA beat and mining restarts put Core Natural Resources in focus Core Natural Resources (CNR) is back on investors’ radar after reporting third quarter adjusted EBITDA of $141 million, resuming longwall mining at Leer South and clearing safety issues at Mountaineer II. See our latest analysis for Core Natural Resources. The stock has eased back from a fresh 52 week high of US$102.99 to around US$99. A 12% 1 month share price return and 23.5% 3 month share price return sit alongside a 3...

Why Avista Stock Is On Investors’ Radar Avista (AVA) is drawing attention after recent share price moves, with a 1 day return of about a 1.3% decline, in contrast with gains over the past month and past 3 months. See our latest analysis for Avista. At the current share price of US$40.04, Avista’s recent 4.05% 30 day share price return and 3.41% year to date share price return contrast with a stronger 14.27% 1 year total shareholder return, suggesting steady but not accelerating momentum. If...

How LGI Homes Stock Has Been Moving LGI Homes (LGIH) has recently seen mixed share performance, with a 3.2% decline over the past day and a 4.8% decline over the past week, alongside a gain over the past month. Over the past 3 months the stock has recorded a gain, while the year-to-date figure is also positive. In contrast, the past year, 3-year, and 5-year total returns all show declines. See our latest analysis for LGI Homes. At a share price of $51.21, LGI Homes has seen short term...

Recently, ZIM Integrated Shipping Services reported that its short interest as a percentage of float fell by 14.99%, to 15.54%, still well above the peer group average of 2.71%. This pullback in short positioning, while remaining elevated versus peers, highlights a shift in sentiment that could be especially important for such a heavily shorted stock. We will now examine how this sharp reduction in short interest shapes ZIM Integrated Shipping Services’ investment narrative and investor...

Idorsia Ltd. recently reported in Nature Communications the Phase 3 MODIFY and open-label extension results for lucerastat, an oral substrate reduction therapy in adults with Fabry disease, which did not meet its primary neuropathic pain endpoint but showed sustained biomarker reductions and encouraging renal outcomes. The data, including a slower rate of eGFR decline and stabilization of cardiac measures in patients with impaired kidney function, have guided the design of a new Phase 3...

On 23 January 2026, Kuros Biosciences drew heightened investor attention as trading activity increased ahead of its 10 March 2026 earnings release and anticipated clinical updates in orthobiologics. The focus on MagnetOs and the fibrin/PTH spinal fusion and fracture programs highlights how upcoming medical data milestones may influence perceptions of the company’s pipeline progress. With a recent 7-day gain and interest in its fibrin/PTH program, we’ll examine how these developments shape...

Recent reports highlight Chalice Mining’s Gonneville palladium-nickel-copper project in Western Australia, which the company says could materially influence global palladium supply and is currently planned for a two-stage development with A$820 million in initial capital expenditure, largely funded by debt, following anticipated regulatory approvals in early 2028. At the same time, Managing Director Alexander Carl Dorsch’s sale of 1.5 million shares at A$2.30 each has sharpened market focus...

Regeneron Pharmaceuticals (REGN) is back in focus after the approval of its high dose Eylea HD, which cuts injection frequency, combined with continued Dupixent momentum and fresh bullish commentary from analysts and long term shareholders. See our latest analysis for Regeneron Pharmaceuticals. Those Eylea HD and Dupixent updates arrive as Regeneron’s 90 day share price return of 15.14% contrasts with a softer year to date share price return of a 2.93% decline, while the 1 year total...

Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after China’s NMPA approved its drug Redemplo for familial chylomicronemia syndrome. This marks the therapy’s third clearance, following earlier approvals in the US and Canada. See our latest analysis for Arrowhead Pharmaceuticals. At a share price of US$67.05, Arrowhead has given investors a 69.53% 90 day share price return. The 1 year total shareholder return of 231.11% and 3 year total shareholder return of 101.47% underline how...

On January 22, 2026, Eastern Bankshares reported Q4 2025 earnings that exceeded analyst expectations, detailed higher full-year net interest income of US$828.6 million, and confirmed a regular quarterly cash dividend of US$0.13 per share payable on March 20, 2026 to shareholders of record on March 6, 2026. The company also completed a US$55.4 million buyback of 3,100,000 shares, reported lower net charge-offs of US$9.8 million for Q4 2025, and highlighted record wealth assets under...

Lingbao Gold Group has appointed corporate law expert Mr. Huang Hui as an independent non-executive director and committee chair, and shareholders have approved amendments to the company’s Articles of Association at an extraordinary general meeting held on 22 January 2026. This combination of governance-focused board refresh and updated Articles signals an increased emphasis on oversight, legal expertise, and rule-setting at the top of the company. We’ll now examine how the appointment of...

L3Harris Technologies has raised its quarterly cash dividend from US$1.20 to US$1.25 per share, and the Pentagon has committed US$1.00 billion to its solid rocket motors business ahead of a planned Missile Solutions spin-off and IPO in the second half of 2026. Together, the higher dividend and the Department of Defense’s direct equity stake highlight L3Harris’s effort to reposition its portfolio around core defense technologies while still emphasizing shareholder returns. We’ll now examine...

Fidelity National Information Services (FIS) recently reshaped its business mix by selling its remaining Worldpay stake and buying Global Payments' issuer solutions arm, while lifting its 2025 revenue and earnings guidance to reflect operational progress. See our latest analysis for Fidelity National Information Services. Even after the recent portfolio reshuffle and upgraded 2025 guidance, the 1-year total shareholder return of 23.71% decline and 5-year total shareholder return of 47.69%...

United Airlines Holdings reported its fourth-quarter 2025 results, with revenue of US$15,397 million and net income of US$1,044 million, alongside record full-year revenue of US$59,070 million and earnings per share of US$10.20. Beyond the headline records, the company’s premium cabins delivered around 12% year-on-year revenue growth, and United became the only US airline to grow earnings per share over the year while also raising guidance for 2026. We’ll now examine how United’s upgraded...

In January 2026, IPG Photonics showcased a broad lineup of new laser solutions at the SPIE Photonics West Exhibition in San Francisco, spanning cleaning, welding, cutting, micro‑machining, semiconductor manufacturing, and directed energy applications. The introduction of ultra‑compact multi‑kilowatt lasers, deep UV and femtosecond sources, and integrated high‑power welding platforms underscores IPG Photonics’ push into higher‑precision manufacturing, defense, and EV battery production...

Why the recent news around West Pharmaceutical Services stock matters West Pharmaceutical Services (WST) has been in focus after recent commentary highlighted expected improvements in earnings estimates, a positive Zacks ranking, and solid demand for its proprietary drug delivery products and capacity expansion plans. See our latest analysis for West Pharmaceutical Services. Despite upbeat commentary around earnings estimates and strong demand for its drug delivery products, the share price...

Index inclusion puts Genesis Minerals in sharper focus Genesis Minerals (ASX:GMD) has been added to the ASX 200 index, a shift that immediately puts the gold producer on the radar of index funds and more institutional investors. This change can affect trading volumes, liquidity and how Genesis Minerals fits into diversified Australian equity portfolios. It may prompt many investors to reassess its A$7.86 share price, recent returns and fundamentals. See our latest analysis for Genesis...

Pursuit Attractions and Hospitality, Inc. previously announced it had entered into an agreement to sell its Flyover flying theater subsidiaries for US$78.40 million in cash, subject to regulatory approvals and including a US$10.00 million termination fee under certain conditions. This divestiture marks a meaningful reshaping of Pursuit’s attractions portfolio and signals potential capital redeployment within its wider hospitality and attractions businesses. We will now examine how the...

Readers hoping to buy Kirloskar Pneumatic Company Limited ( NSE:KIRLPNU ) for its dividend will need to make their move...

It looks like Advani Hotels & Resorts (India) Limited ( NSE:ADVANIHOTR ) is about to go ex-dividend in the next three...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...

As Saudi Arabia's stock market gains momentum ahead of upcoming earnings and the anticipated opening to foreign investors, the Middle East is poised for increased attention from global capital. This evolving landscape presents a fertile ground for identifying promising stocks, where strong fundamentals and strategic positioning can offer potential opportunities amidst rising investor interest.